Company Encyclopedia
View More
name
OCUMENSION-B
01477.HK
Ocumension Therapeutics, together with its subsidiaries, operates as an ophthalmic pharmaceutical platform company in the People's Republic of China. It discovers, develops, and commercializes therapies for ophthalmic patients. Its portfolio includes products and drugs for the treatment of chronic non-infectious uveitis, infective and allergic conjunctivitis, diabetic macular edema, dry eye, glaucoma and ocular hypertension, postoperative inflammation, choroidal neovascularization, bacterial conjunctivitis, retinitis pigmentosa, age-related macular degeneration, cornea graft rejection, myopia, and optic neuritis. The company was founded in 2017 and is based in Suzhou, the People's Republic of China.
1.466 T
01477.HKMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
PharmaceuticalsIndustry
Industry Ranking26/48
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-7.76%D
    • Profit Margin-45.84%E
    • Gross Margin35.93%C
  • Growth ScoreA
    • Revenue YoY75.49%A
    • Net Profit YoY22.65%B
    • Total Assets YoY31.17%A
    • Net Assets YoY34.41%A
  • Cash ScoreC
    • Cash Flow Margin-218.14%D
    • OCF YoY75.49%A
  • Operating ScoreD
    • Turnover0.16D
  • Debt ScoreA
    • Gearing Ratio6.26%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Shandong Boan Biotechnology Wins China Approval for Boyoujing Aflibercept Injection

    Shandong Boan Biotechnology Co. Ltd. has received marketing approval from China's National Medical Products Administration for its aflibercept injection, Boyoujing®, a biosimilar to EYLEA®, for treating nAMD and DME. The company will partner with Ocumension Therapeutics to commercialize the product in Mainland China, marking a significant milestone in expanding ophthalmic treatment access.

    Reuters·
    HK
    01477
    +1.22%
    Reuters·
    HK
    01477
    +1.22%

    Ocumension Therapeutics Receives NMPA Approval to Market OT-702 in China

    Ocumension Therapeutics has received approval from China's NMPA to market OT-702, an EYLEA® biosimilar, for treating neovascular age-related macular degeneration and diabetic macular edema in adults. Developed with Shandong Boan Biotechnology, Ocumension holds exclusive rights for its promotion and commercialization in China.

    Reuters·
    HK
    01477
    +1.22%
    Reuters·
    HK
    01477
    +1.22%

    Hong Kong stock pharmaceutical stocks rebound, OCUMENSION-B rises nearly 12%

    As of the time of publication, OCUMENSION-B rose by 11.99%, IMMUNEONCO-B rose by 10.73%, KEYMED BIO-B rose by 8.61%, and CANBRIDGE-B rose by 6.79%

    Zhitong·
    HK
    01477
    +1.22%
    HK
    02162
    +0.25%
    HK
    01228
    +2.60%
    Zhitong·
    HK
    01477
    +1.22%
    HK
    02162
    +0.25%
    HK
    01228
    +2.60%

    CICC: Maintains OCUMENSION-B outperforming industry rating and raises target price to HKD 10.16

    CICC maintains a "Outperform" rating on OCUMENSION-B and raises the target price to HKD 10.16, representing a 3.4% upside from the current stock price. The company's revenue in the first half of 2025 is expected to be RMB 294 million, a year-on-year increase of 75.4%, with a loss of RMB 132 million. In terms of R&D, multiple core products are progressing smoothly, the sales network is expanding rapidly, and the commercialization team has more than 290 members, covering 21,535 hospitals nationwide

    Zhitong·
    HK
    01477
    +1.22%
    Zhitong·
    HK
    01477
    +1.22%

    Understanding the Market | OCUMENSION-B fell over 13% and was removed from the Hang Seng Composite Index, with a net loss of 132 million yuan in the first half of the year

    OCUMENSION-B fell over 13%, as of the time of publication, down 13.07%, reported at HKD 9.84, with a trading volume of HKD 224 million. On the news front, on August 22, the Hang Seng Index Company announced its regular semi-annual index adjustment results, with all changes to be implemented after the market closes on September 5 and effective from September 8. Among them, OCUMENSION-B was removed from the Hang Seng Composite Index. The market is concerned about its further removal from the Hong Kong Stock Connect list. In addition, OCUMENSION-B recently released its mid-term results for 2025, reporting revenue of RMB 294 million, a year-on-year increase of 75.4%; a net loss of RMB 132 million, a year-on-year narrowing of 12.6%; and a basic loss per share of RMB 0.17

    Zhitong·
    HK
    01477
    +1.22%
    Zhitong·
    HK
    01477
    +1.22%
    © 2025 Longbridge｜Disclaimer